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Introduction {#sec005}
============

Autoimmune diseases (ADs) are initiated by abnormal immune response to self-antigen, and then come the results including immune-mediated tissue destruction and chronic disabilities \[[@pone.0121918.ref001]\]. There are more than 100 diseases and syndromes in ADs, which cause a heavy economic burden in the world, about more than \$100 billion annually \[[@pone.0121918.ref002]\]. More and more evidence indicated that genetic backgrounds play an important role in the pathogenesis of ADs, which may be controlled by a common set of susceptibility genes \[[@pone.0121918.ref003], [@pone.0121918.ref004]\].

MicroRNAs (miRNAs) are non-coding single-stranded RNA molecules. By binding to 3' un-translated regions (UTRs) of targeted messenger RNAs, the miRNAs can repress, degrade or silence the gene expression \[[@pone.0121918.ref005], [@pone.0121918.ref006]\]. Therefore, miRNAs have been demonstrated to affect various functions in both innate and adaptive immune response \[[@pone.0121918.ref007], [@pone.0121918.ref008]\]. Among them, the microRNA-146a (miR-146a) was reported to be involved in both innate and adaptive immunity, especially played an important role in autoimmune disease \[[@pone.0121918.ref008], [@pone.0121918.ref009]\].

Single nucleotide polymorphisms (SNPs) or mutations in miRNAs may alter the expression level of the gene and the susceptibility of some diseases \[[@pone.0121918.ref010]--[@pone.0121918.ref013]\]. Many studies on the relationship between miR-146a rs2910164 G\>C polymorphism and susceptibility of ADs have been performed so far \[[@pone.0121918.ref014]--[@pone.0121918.ref034]\]. However, the results remain inconsistent. Moreover, two meta-analyses on this issue published in 2013 and 2014 also generated opposite conclusions \[[@pone.0121918.ref035], [@pone.0121918.ref036]\]. Based on the new case-control studies \[[@pone.0121918.ref027], [@pone.0121918.ref028], [@pone.0121918.ref030]--[@pone.0121918.ref034]\], we conducted this updated meta-analysis according the criteria PRISMA statement \[[@pone.0121918.ref037]\], in order to clarify the association between miR-146a rs2910164 G\>C polymorphism and susceptibility of ADs.

Materials and Methods {#sec006}
=====================

Publication search {#sec007}
------------------

A systematic search was performed in PubMed, OvidSP and Chinese National Knowledge Infrastructure (CNKI) databases covering all papers published prior to September 8^th^, 2014. The searching strategy was as follow: (autoimmune OR autoimmune disease OR autoimmunity) AND (polymorphism OR polymorphisms OR variation OR variations OR mutation OR mutations OR variant OR variants) AND (Has-mir-146a OR miR146a OR microRNA-146a OR miR-146 OR miR-146a OR rs2910164). The references in the studies were also read to find additional publications on the topic. Articles included should meet the criteria below: (1) case-control study; (2) evaluation of miR-146a rs2910164 G\>C polymorphism and risk of ADs; (3) available and usable data of genotype frequency. The articles were excluded if they meet the exclusion criteria below: (1) a case report, review or descriptive study; (2) a lack of normal population as controls; (3) not show the evaluation of miR-146a rs2910164; (4) duplicate data in the studies.

Date extraction {#sec008}
---------------

Two authors (CL and WF) independently extracted the data from eligible studies. Different data extracted by CL and WF were checked by the third author YZ. The remained disagreements were discussed and judged by these three authors. The following information was extracted: the first author, publication year, diseases, country, ethnicity, genotyping methods, number of cases and controls, the gender distribution of cases and controls, number of genotypes and alleles, Hardy-Weinberg equilibrium (HWE) in control subjects, frequency of G allele in controls. Ethnicities were categorized as Caucasian, East Asian, Latin-American and Mediterranean. Study qualities were judged according to the criteria modified from previous publications \[[@pone.0121918.ref038]--[@pone.0121918.ref040]\] (See [S1 Table](#pone.0121918.s003){ref-type="supplementary-material"}. "Scale for methodological quality assessment").

Statistical analysis {#sec009}
--------------------

Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated as a measure of the association between miR-146a rs2910164 G\>C polymorphism and ADs risk. The widely reported genetic models, allele model, heterozygote model, homozygote model, dominant model and recessive model, were used. In addition to comparing the pooled effects among all subjects, the stratified comparisons were also conducted according to different ethnicities and different diseases. In order to evaluate the accumulation of evidence, the cumulative meta-analysis was performed. The between study heterogeneity was measured by Cochran's (Q) and Higgins's (I^2^) tests. If the heterogeneity was considered significant (*p*\<0.05), the random effect model was used to estimate the pooled OR. Otherwise, the fixed effect model was conducted. Also, logistic meta-regression analysis was carried out, if there was obvious significant heterogeneity, to explore potential sources of heterogeneity. The examined characteristics include: publication years, countries, genotyping methods, number of alleles and genotypes, number of female and male in cases, and the frequency of G allele in controls. The HWE was examined using Chi-square test with significance set at *p*\<0.05. Sensitivity analysis was performed to evaluate the effect of each study on the combined ORs by deleting each study in each time, and to evaluate the effect of studies with low quality or without HWE on the pooled ORs by deleting these studies. Potential publication bias was determined by using Funnel plots and Begg's test. An asymmetric plot and the *p* value less than 0.05 was recognized as significance. All statistical analyses were performed by Stata 12.0 software (Stata Corp., College Station, TX).

Results {#sec010}
=======

Study Characteristics {#sec011}
---------------------

There were 406 articles matching the searching strategy, and additional 5 articles \[[@pone.0121918.ref020], [@pone.0121918.ref023], [@pone.0121918.ref025], [@pone.0121918.ref028], [@pone.0121918.ref031]\] were included by scanning the references of original papers. After step by step of screening the titles, abstracts and full-texts of the articles, as shown in [Fig 1](#pone.0121918.g001){ref-type="fig"}, 21 articles were recognized appropriate for this meta-analysis, including 24 studies for rs2910164, 11 studies more than the previous meta-analysis published in 2014 \[[@pone.0121918.ref036]\].

![Flowchart for identification of studies included in the meta-analysis.\
In 411 articles, 51 were found not related to ADs and 43 were found not related to miR-146a by scanning the titles. After that, 233 articles were recognized as reviews, 37 were found not related to human patients and 8 articles were repeated papers by reviewing the abstracts. The full-texts of the left 39 articles were carefully reviewed, in which 18 articles were found not about rs2910164. At last, 21 articles were remained for this meta-analysis, which included 24 case-control studies for rs2910164.](pone.0121918.g001){#pone.0121918.g001}

Within the 21 articles, five kinds of genotyping methods were used. There were 4 racial included, Caucasian, East Asian, Latin-American and Mediterranean. According the different types of diseases, these studies were divided into five subgroups. The studies on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Juvenile RA (JRA) and Juvenile Idiopathic Arthritis-Enthesitis-Related Arthritis (JIA-ERA) were included into Inflammatory Arthritis (IA) subgroup. The studies on Ulcerative Colitis (UC) and Crohn's Disease (CD) were included into Inflammatory Bowel Disease (IBD) subgroup. Among these studies, the patients with Behcet's Disease (BD), Vogt-Koyanagi-Harada syndrome (VKH), Fuchs Uveitis Syndrome (FUS) and Pediatric Uveitis (PU) were all suffering uveitis, which was a common syndrome of ADs. So the Uveitis subgroup was formed. The remained studies, except that for Systemic Lupus Erythematosus (SLE), were included in other diseases subgroup. There were 5 studies not in HWE in control groups (*p*\<0.05), but the *p* value of HWE were not less than 0.01. And there was not enough data in another study to generate the HWE in control. The detail characteristics are shown in [Table 1](#pone.0121918.t001){ref-type="table"}.

10.1371/journal.pone.0121918.t001

###### Characteristics of published studies of rs2910164.

![](pone.0121918.t001){#pone.0121918.t001g}

  First author       Year    Diseases   Country   Ethnicity        Sample size   Female/Male   Genotyping methods   Case      Control             HWE of control (p value)   Frequency of G Allele in controls   Quality                                                                  
  ------------------ ------- ---------- --------- ---------------- ------------- ------------- -------------------- --------- ------------------- -------------------------- ----------------------------------- --------- ------ ----- ----- ----- ----- ------ ------ ---------- ------ ----
  Chatzikyriakidou   2010a   RA         Greece    Caucasian        136           147           109/27               115/32    PCR-RFLP            73                         53                                  10        199    73    80    53    14    213    81     Y(0.240)   0.72   7
  Chatzikyriakidou   2010b   PsA        Greece    Caucasian        29            66            10/19                30/36     PCR-RFLP            14                         12                                  3         40     18    39    18    9     96     36     N(0.011)   0.73   5
  Luo                2011    SLE        China     East Asian       816           1080                                         Direct sequencing                                                                            669    963                     864    1296              0.40   8
  Zhang              2011    SLE        China     East Asian       213           209           201/12               195/14    PCR-RFLP            33                         101                                 79        167    259   23    104   82    150    268    Y(0.239)   0.36   8
  Yang               2011    RA         China     East Asian       208           240           172/36               195/45    PCR-RFLP            28                         95                                  85        151    265   30    116   94    176    304    Y(0.529)   0.37   8
  Fenoglio           2011    MS         Italy     Caucasian        346           339           240/106              207/132   TaqMan              181                        135                                 30        497    195   195   115   29    505    173    N(0.048)   0.74   7
  Okubo              2011    UC         Japan     East Asian       170           403           74/96                208/195   PCR-RFLP            28                         67                                  75        123    217   74    178   151   326    480    Y(0.095)   0.40   7
  Lofgren            2012    SLE        Sweden    Caucasian        1109          1428                                         TaqMan              623                        422                                 64        1668   550   819   531   78    2169   687    Y(0.503)   0.76   7
  Jimenez-Morales    2012    SLE        Mexico    Latin-American   367           531           304/63               299/232   TaqMan              163                        167                                 37        493    241   236   229   66    701    361    Y(0.369)   0.66   8
  Jimenez-Morales    2012    JRA        Mexico    Latin-American   210           531           125/85               299/232   TaqMan              102                        80                                  28        284    136   236   229   66    701    361    Y(0.369)   0.66   8
  Qian               2012    RA         China     East Asian       123           220           105/18               196/24    PCR-LDR             16                         65                                  42        97     149   35    109   76    179    261    Y(0.694)   0.41   8
  Sakoguchi          2012    SSc        Japan     East Asian       52            107                                          PCR-RFLP            1                          28                                  23        30     74    3     53    51    59     155    N(0.013)   0.28   1
  Zhou               2012    FUS        China     East Asian       219           612           102/117              262/350   PCR-RFLP            36                         91                                  92        163    275   79    279   254   437    787    Y(0.862)   0.36   9
  Hashemi            2013    RA         Iran      Mediterranean    104           110           91/13                70/40     T-ARMS-PCR          57                         39                                  8         153    55    64    37    9     165    55     Y(0.280)   0.75   8
  EI-Shal            2013    RA         Egypt     Mediterranean    217           245           217/0                245/0     PCR-RFLP            30                         103                                 84        163    271   15    119   111   149    341    N(0.021)   0.30   7
  Gazouli            2013    UC         Greece    Caucasian        210           300           109/101              159/141   PCR-RFLP            126                        78                                  6         330    90    200   90    10    490    110    Y(0.974)   0.82   7
  Gazouli            2013    CD         Greece    Caucasian        242           300           134/108              159/141   PCR-RFLP            105                        113                                 24        323    161   200   90    10    490    110    Y(0.974)   0.82   7
  Zhou               2014    BD         China     East Asian       809           1132          131/678              513/619   PCR-RFLP            131                        440                                 238       702    916   154   518   460   826    1438   Y(0.670)   0.36   10
  Zhou               2014    VKH        China     East Asian       613           1132          287/326              513/619   PCR-RFLP            64                         273                                 276       401    825   154   518   460   826    1438   Y(0.670)   0.36   10
  Singh              2014    JIA-ERA    India     Mediterranean    150           216           17/133               15/201    PCR-RFLP            75                         56                                  19        206    94    112   91    13    315    117    Y(0.327)   0.73   8
  Lin                2014    IgAN       China     East Asian       404           711           169/235              261/450   PCR-LDR             103                        195                                 106       401    407   219   360   132   798    624    Y(0.454)   0.56   8
  Zhao               2014    ITP        China     East Asian       280           270           181/99               156/114   PCR-RFLP            35                         134                                 111       204    356   36    135   99    207    333    Y(0.344)   0.38   8
  Wei                2014    PU         China     East Asian       520           1204          278/242              659/545   PCR-RFLP            113                        248                                 159       474    566   163   553   488   879    1529   Y(0.750)   0.37   9
  Okada              2014    PM/DM      Japan     East Asian       44            107           28/16                          PCR-RFLP            0                          29                                  15        29     59    3     53    51    59     155    N(0.013)   0.28   3

Abbreviations: RA, Rheumatoid Arthritis; PsA, Psoriatic Arthritis; SLE, Systemic Lupus Erythematosus; MS, Multiple Sclerosis; UC, Ulcerative Colitis; JRA, Juvenile Rheumatoid Arthritis; SSc, Systemic Sclerosis; FUS, Fuchs Uveitis Syndrome; CD, Crohn's Disease; BD, Behcet's Disease; VKH, Vogt-Koyanagi-Harada syndrome; JIA-ERA, Juvenile Idiopathic Arthritis-Enthesitis-Related Arthritis; IgAN, Immunoglobulin A nephropathy; ITP, Immune Thrombocytopenia; PU, Pediatric Uveitis; PM/DM, Polymyositis/Dermatomyositis.

Association between miR-146a rs2910164 G\>C polymorphism and ADs risk {#sec012}
---------------------------------------------------------------------

First, we investigated the overall association between rs2910164 and susceptibility of ADs. No significant difference of the pooled OR was found in any genetic model. However, in terms of stratified analysis, the significance emerged. In Caucasian subgroup, significant increased risks of GC genotype and GC+CC genotype with ADs susceptibility were found in heterozygote model (GC vs GG, OR = 1.38, 95% CI 1.04--1.83, *p* = 0.024) and dominant model (GC+CC vs GG, OR = 1.37, 95% CI 1.01--1.85, *p* = 0.041), respectively ([Table 2](#pone.0121918.t002){ref-type="table"}, [Fig 2A and B](#pone.0121918.g002){ref-type="fig"}).

![Forest plots of ADs risk associated with rs2910164.\
**(A-B)** Forest plots of ADs risk associated with rs2910164 stratified analyzed by ethnicities. **(A)** Heterozygote model, GC vs GG, Caucasian subgroup, random model. **(B)** Dominant model, GC+CC vs GG, Caucasian subgroup, random model. **(C-E)** Forest plots of ADs risk associated with rs2910164 stratified analyzed by diseases. **(C)** Allele model, C vs G, Other diseases subgroup, fixed model. **(D)** Homozygote model, CC vs GG, Other diseases subgroup, fixed model. **(E)** Dominant model, GC+CC vs GG, Other diseases subgroup, fixed model. OR: odds ratio; 95% CI: 95% confidence interval.](pone.0121918.g002){#pone.0121918.g002}

10.1371/journal.pone.0121918.t002

###### Stratified analysis of association between ADs risk and rs2910164.

![](pone.0121918.t002){#pone.0121918.t002g}

  Stratify           Study(n)           Allele model (C vs G)   Heterozygote model (GC vs GG)   Homozygote model (CC vs GG)   Dominant model (GC+CC vs GG)   Recessive model (CC versus GG+GC)                                                                                                                                                                                                  
  ------------------ ------------------ ----------------------- ------------------------------- ----------------------------- ------------------------------ ----------------------------------- -------- ---------- ----------- ------- -------- ---------- ----------- ------- ------- -------- ---------- ----------- ----------- ------- -------- -------- ------- ------- ------- -------- --------
  Total              24                 1.02                    0.653                           77.9                          0.000                          Random                              1.04     0.556      58.6        0.000   Random   1.01       0.914       73.1    0.000   Random   1.04       0.622       70.7        0.000   Random   1.00     0.995   70.2    0.000   Random   
  (0.93--1.13)       (0.91--1.19)       (0.81--1.27)            (0.89--1.21)                    (0.85--1.17)                                                                                                                                                                                                                                                                                    
  Ethnicities        Caucasian          6                       1.25                            0.083                         79.5                           0.000                               Random   **1.38**   **0.024**   72.0    0.003    Random     1.28        0.306   61.9    0.022    Random     **1.37**    **0.041**   77.9    0.000    Random   1.14    0.511   44.7    0.107    Random
  (0.97--1.60)       **(1.04--1.83)**   (0.80--2.07)            **(1.01--1.85)**                (0.77--1.67)                                                                                                                                                                                                                                                                                    
  East Asian         13                 0.97                    0.663                           79.3                          0.000                          Random                              0.95     0.418      34.0        0.118   Fixed    0.96       0.817       78.8    0.000   Random   0.95       0.642       64.3        0.001   Random   0.96     0.731   80.0    0.000   Random   
  (0.85--1.10)       (0.84--1.07)       (0.71--1.32)            (0.77--1.18)                    (0.78--1.19)                                                                                                                                                                                                                                                                                    
  Latin-American     2                  0.94                    0.440                           0.0                           0.897                          Fixed                               0.95     0.633      27.7        0.240   Fixed    0.88       0.466       0.0     0.579   Fixed    0.93       0.519       0.0         0.432   Fixed    0.91     0.550   0.0     0.331   Fixed    
  (0.81--1.10)       (0.76--1.18)       (0.63--1.23)            (0.76--1.15)                    (0.66--1.25)                                                                                                                                                                                                                                                                                    
  Mediterranean      3                  0.97                    0.874                           68.9                          0.040                          Random                              0.81     0.417      61.9        0.072   Random   0.93       0.892       82.4    0.003   Random   0.83       0.519       72.4        0.027   Random   1.14     0.725   70.0    0.036   Random   
  (0.69--1.38)       (0.48--1.36)       (0.30--2.82)            (0.46--1.48)                    (0.56--2.32)                                                                                                                                                                                                                                                                                    
  Diseases           IA                 8                       0.97                            0.607                         77.9                           0.384                               Fixed    0.92       0.384       28.2    0.204    Fixed      0.95        0.767   42.8    0.093    Random     0.94        0.496       29.8    0.190    Fixed    0.99    0.906   8.2     0.366    Fixed
  (0.87--1.09)       (0.77--1.11)       (0.67--1.35)            (0.79--1.12)                    (0.82--1.19)                                                                                                                                                                                                                                                                                    
  SLE                4                  0.98                    0.625                           79.5                          0.622                          Fixed                               1.02     0.748      0.0         0.379   Fixed    0.91       0.468       5.2     0.348   Fixed    1.01       0.857       6.9         0.342   Fixed    0.93     0.544   0.0     0.567   Fixed    
  (0.90--1.06)       (0.89--1.17)       (0.71--1.17)            (0.89--1.16)                    (0.75--1.16)                                                                                                                                                                                                                                                                                    
  IBD                3                  1.48                    0.057                           83.5                          0.002                          Random                              1.52     0.096      76.6        0.014   Random   1.82       0.190       76.3    0.015   Random   1.61       0.069       80.3        0.006   Random   1.57     0.178   63.3    0.066   Random   
  (0.99--2.21)       (0.93--2.49)       (0.74--4.46)            (0.96--2.68)                    (0.82--3.02)                                                                                                                                                                                                                                                                                    
  Uveitis            4                  0.87                    0.271                           90.5                          0.000                          Random                              0.88     0.429      72.7        0.012   Random   0.75       0.262       88.8    0.000   Random   0.83       0.310       83.1        0.000   Random   0.83     0.293   89.8    0.000   Random   
  (0.67--1.12)       (0.65--1.20)       (0.46--1.24)            (0.57--1.20)                    (0.58--1.18)                                                                                                                                                                                                                                                                                    
  Others             5                  **1.16**                **0.010**                       15.5                          0.316                          Fixed                               1.19     0.092      0.0         0.884   Fixed    **1.42**   **0.006**   0.0     0.649   Fixed    **1.25**   **0.020**   0.0         0.942   Fixed    1.08     0.611   53.1    0.074   Random   
  **(1.04--1.31)**   (0.97--1.44)       **(1.10--1.84)**        **(1.04--1.51)**                (0.80--1.47)                                                                                                                                                                                                                                                                                    

Meanwhile, in other disease subgroup, significant increased risks of C allele, CC genotype and GC+CC genotype with ADs were found in allele model (C vs G, OR = 1.16, 95% CI 1.04--1.31, *p* = 0.010), homozygote model (CC vs GG, OR = 1.42, 95% CI 1.10--1.84, *p* = 0.006) and dominant model (GC+CC vs GG, OR = 1.25, 95% CI 1.04--1.51, *p* = 0.020), respectively ([Table 2](#pone.0121918.t002){ref-type="table"}, [Fig 2C, D, E](#pone.0121918.g002){ref-type="fig"}). There was not any significance in IA, SLE, IBD and Uveitis subgroup. However, a trend of increased disease risk of C allele could be found in allele model (C vs G, OR = 1.48, 95% CI 0.99--2.21, *p* = 0.057) in IBD subgroup ([Table 2](#pone.0121918.t002){ref-type="table"}).

The cumulative meta-analysis showed that the significance of ORs emerged after the studies published in 2013 enrolled in Caucasian subgroup ([Fig 3A and B](#pone.0121918.g003){ref-type="fig"}), while after the studies published in 2014 enrolled in other disease subgroup ([Fig 3C, D, and E](#pone.0121918.g003){ref-type="fig"}).

![Cumulative meta-analysis of the association between rs2910164 and ADs risk.\
Every rhombus represents the pooled OR when studies accumulated over time, and the horizontal line represents the 95% CI of the pooled ORs. **(A)** Heterozygote model, GC vs GG, Caucasian subgroup, random model. **(B)** Dominant model, GC+CC vs GG, Caucasian subgroup, random model. **(C)** Allele model, C vs G, Other diseases subgroup, fixed model. **(D)** Homozygote model, CC vs GG, Other diseases subgroup, fixed model. **(E)** Dominant model, GC+CC vs GG, Other diseases subgroup, fixed model.](pone.0121918.g003){#pone.0121918.g003}

Evaluation of heterogeneity {#sec013}
---------------------------

The heterogeneities among studies were obvious in the overall comparisons (I^2^ = 77.9%, Tau^2^ = 0.044, *p* = 0.000). The meta-regression analysis was conducted to further explore sources of heterogeneity. We assessed allele comparison by potential sources of publication year, country, genotyping methods, number of genotypes and alleles, and number of female and male in cases. None of the potential sources above could explain the heterogeneity by meta-regression analysis. However, when we compared the frequencies of G allele in controls, we found that the heterogeneity could partly (Adjusted R^2^ = 32.7%) explained by the variation of frequencies of G allele in controls.

Sensitivity and publication bias analysis {#sec014}
-----------------------------------------

We performed the sensitivity analysis to test the influence of a single study on the overall meta-analysis by deleting each study once a time. As a result, the pooled estimate didn't show significant difference, which indicated that the results in this meta-analyses were statistically reliable. Moreover, the pooled ORs did not vary much even after the three studies \[[@pone.0121918.ref015], [@pone.0121918.ref024], [@pone.0121918.ref034]\] with low quality or six studies \[[@pone.0121918.ref015], [@pone.0121918.ref016], [@pone.0121918.ref019], [@pone.0121918.ref024], [@pone.0121918.ref027], [@pone.0121918.ref034]\] without HWE removed ([Fig 4](#pone.0121918.g004){ref-type="fig"}). No evidence of publication bias was found in current meta-analysis, identified by the Funnel plots, Egger's test (*p* = 0.261) and Begg's test (*p* = 0.862) ([Fig 5](#pone.0121918.g005){ref-type="fig"}).

![Sensitivity analysis of association of rs2910164 and ADs risk.\
**(A)** Pooled analysis of association of rs2910164 and ADs risk. Allele model, C vs G. **(B)** Sensitivity analysis by iteratively removing one study at a time. **(C)** Sensitivity analysis by removing three studies with low quality. **(D)** Sensitivity analysis by removing six studies without HWE.](pone.0121918.g004){#pone.0121918.g004}

![Publication bias on the rs2910164 polymorphism and ADs risk.](pone.0121918.g005){#pone.0121918.g005}

Discussion {#sec015}
==========

Solid evidences had shown that miRNAs played important roles in the regulation of cell differentiation, proliferation, metabolism, apoptosis and tumorigenesis \[[@pone.0121918.ref041]\]. MiR-146a was one of the first miRNAs identified to be involved in innate immune response, and further demonstrated to be related to several types of cancers \[[@pone.0121918.ref042]--[@pone.0121918.ref044]\].

One SNP of miR-146a, rs2910164 G\>C, was found not only related to cancer, but also related to some kinds of ADs \[[@pone.0121918.ref029]\]. Accumulating evidences emerged to distinguish if there was any relationship between rs2910164 and susceptibility of ADs. However, the results were inconsistent. A meta-analysis published in 2013 showed that there was not any association between rs2910164 and ADs risk \[[@pone.0121918.ref035]\]. While they did not include a study published by Luo et al \[[@pone.0121918.ref016]\] in 2011. Maybe due to there was only frequency data of allele and was not any data of each genotype in Luo's study, which did not meet the inclusion criteria of this meta-analysis \[[@pone.0121918.ref035]\]. On the contrary, another meta-analysis published in 2014 did find some association there \[[@pone.0121918.ref036]\], however, some already published studies \[[@pone.0121918.ref015], [@pone.0121918.ref020], [@pone.0121918.ref025]\] prior their search date at April 2013 were not included although they should be. Moreover, the only significances of ORs were found in GG+CC/GC genetic model \[[@pone.0121918.ref036]\], not in the five well used genetic models as shown in the previous meta-analysis \[[@pone.0121918.ref035]\]. After that, other researchers published several new case-control studies about this topic in 2013 and 2014 \[[@pone.0121918.ref027], [@pone.0121918.ref028], [@pone.0121918.ref030]--[@pone.0121918.ref034]\]. So, it was needed to do an updated meta-analysis which included all the published manuscripts, in order to make a clarified conclusion.

In this meta-analysis, we enrolled 24 studies and pooled the corresponding data including 7591 cases and 9677 controls, and all data of these samples were available in the original publications. Our analysis revealed that there was not any significance of pooled OR. However, in stratified analyses, we found GC genotype and GC+CC genotype were significantly related to the increased susceptibility of ADs in Caucasian subgroup. As in other diseases subgroup, significantly increased risk was observed to be associated with C allele, CC genotype and GC+CC genotype in allele model, homozygote model and dominant model, respectively. All these differences were not found in the two previous meta-analyses \[[@pone.0121918.ref035], [@pone.0121918.ref036]\]. These differences between our data and that in previous meta-analyses may be explained by the different study number and different sample size enrolled in these analyses. As we included more studies and an enlarged sample size, our data should be recognized more powerful.

In cumulative meta-analysis, we found the significance of ORs after new case-control studies published in 2013 and 2014 enrolled. These data demonstrated the correlation of rs2910164 and susceptibility of ADs. In addition, not only sensitivity analysis by iteratively removing one study at a time, but also analysis removing three studies \[[@pone.0121918.ref015], [@pone.0121918.ref024], [@pone.0121918.ref034]\] with low quality or six studies \[[@pone.0121918.ref015], [@pone.0121918.ref016], [@pone.0121918.ref019], [@pone.0121918.ref024], [@pone.0121918.ref027], [@pone.0121918.ref034]\] without HWE, showed similar and consistent results. Thus, the results of cumulative meta-analysis and sensitivity analysis indicated the robustness of our data. There were still some limitations in our studies. First, although there were 24 studies included, the studies for some stratified analyses were limited. For example, there were only two studies for Latin-American subgroup. Second, there were obvious heterogeneities between different groups for some genetic model. Although the meta-regression and sensitivity analyses were conducted and we found that the variation of G allele frequency in controls could partly explain some heterogeneity, the results still needed to be treated with caution. Third, although there was some significance of ORs in some genetic models, the summary ORs were not very high even after the new studies enrolled in the cumulate meta-analyses. So, future well-designed large studies on this topic will be welcomed to confirm this conclusion. Finally, only rs2910164 in miR-146a was included in this study. However, there were more other SNPs in miR-146a and more other genes could also contribute to susceptibility of ADs. Not only the effect of the SNPs or genes, but also the interaction or network among these genetic locations, should be studied in the future. Furthermore, our data did not study the gene-environment interactions based on the lack of this interaction from the original case-control studies. So, in the future, studies investigating the gene-environment interactions would also help to make clear of the role of the genetic locations in the pathogen of ADs.

Conclusions {#sec016}
===========

Taken together, our data demonstrated that the miR-146a rs2910164 G\>C polymorphism was related to the susceptibility of ADs and our findings should be validated by future well-designed large studies.
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